Option Investor
Newsletter

OW JANUARY 2008 recommendations 12-17-07

HAVING TROUBLE PRINTING?
Printer friendly version

We are starting off January recommendations in the following issues

We are recommending put writes in the following issues:


SOLF - Solarfun Power Holdings Co., Ltd., through its subsidiary, Jiangsu Linyang Solarfun Co., Ltd., engages in the development, manufacture, and sale of photovoltaic (PV) cells and PV modules primarily in the People's Republic of China. It offers monocrystalline silicon cells and modules, and multicrystalline silicon cells and modules to system integrators, as well as through third party distributors.

TRB - Tribune Company, through its subsidiaries, operates as a media and entertainment company in the United States. It engages in newspaper publishing, television and radio broadcasting, and entertainment operations. The company operates in two segments, Publishing, and Broadcasting and Entertainment. The Publishing segment publishes daily newspapers, including Los Angeles Times, Chicago Tribune, Newsday, South Florida Sun-Sentinel, The Baltimore Sun, Orlando Sentinel, The Hartford Courant

CSIQ - Canadian Solar, Inc., together with its subsidiaries, engages in the design, development, manufacture, and marketing of solar module products that convert sunlight into electricity for various uses. Its products include a range of standard solar modules to general specifications for use in various residential, commercial, and industrial solar power generation systems. The company also designs and produces specialty solar modules and products based on customers' requirements. Its specialty solar modules and products consist of customized modules that its customers incorporate into their own products, such as solar-powered bus stop lighting, and complete specialty products, such as solar-powered car battery chargers.

RIGL - Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product candidates include R788, which is currently in three Phase II trials for rheumatoid arthritis, immune thrombocytopenic purpura, and lymphoma; and R763, which is in three Phase I trials, in collaboration with Merck Serono, for the treatment of oncology

We are recommending the following specific put writes.

SOLF 26.37
SELL JAN 15 PUT = QFG-MC
Target Price $25.00
Potential Profit(10 x = $250.00

Initial Margin $5,524 10 (contracts)
Return on Investment 4.53%
Cost Basis in Stock = $14.75
Days to Expiration = 32
Stock goes on Watch List Price at: 21.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $15.00


TRB $32.57
SELL JAN 22.50 PUT = TRB-MX
Target Price $45.00
Potential Profit(10 x = $450.00

Initial Margin $6,964 10 (contracts)
Return on Investment 6.46%
Cost Basis in Stock = $22.05
Days to Expiration = 32
Stock goes on Watch List Price at: $27.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $22.50

CSIQ $23.52
SELL JAN 15.00 PUT = GQA-MC
Target Price $45.00
Potential Profit(10 x = $450.00

Initial Margin $5,154 10 (contracts)
Return on Investment 8.73%
Cost Basis in Stock = $14.55
Days to Expiration = 32
Stock goes on Watch List Price at: $20.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $15.00


RIGL $27.43
SELL JAN 15 PUT = QRG-MC
Target Price $30.00
Potential Profit(10 x = $300.00
Initial Margin $5,786 10 (contracts)
Return on Investment 5.18%
Cost Basis in Stock = $14.70
Days to Expiration = 32
Stock goes on Watch List Price at: $22.00
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $15.00



Option Writers Newsletter Archives